IPP Bureau

Kwality Pharmaceuticals receives SFDA GMP approval for 2 units
Kwality Pharmaceuticals receives SFDA GMP approval for 2 units

By IPP Bureau - January 22, 2025

This certification will open new markets for the Kwality Pharma

Catalent to further expand Galapagos’ decentralized CAR-T manufacturing network in US
Catalent to further expand Galapagos’ decentralized CAR-T manufacturing network in US

By IPP Bureau - January 22, 2025

New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience

Sunshine Biopharma launches Olanzapine and Olanzapine ODT
Sunshine Biopharma launches Olanzapine and Olanzapine ODT

By IPP Bureau - January 22, 2025

Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders

Strides receives USFDA approval for Acetaminophen and Ibuprofen Tablets
Strides receives USFDA approval for Acetaminophen and Ibuprofen Tablets

By IPP Bureau - January 21, 2025

The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru

European Commission expands Jemperli plus chemotherapy approval for endometrial cancer
European Commission expands Jemperli plus chemotherapy approval for endometrial cancer

By IPP Bureau - January 21, 2025

Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population

Moderna announces updates on pandemic influenza program
Moderna announces updates on pandemic influenza program

By IPP Bureau - January 21, 2025

The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines

Briefs: Cipla and IOL Chemicals and Pharmaceuticals
Briefs: Cipla and IOL Chemicals and Pharmaceuticals

By IPP Bureau - January 21, 2025

Mesalazine is used to treat inflammatory bowel disease

Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflas
Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflas

By IPP Bureau - January 19, 2025

This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo

Glenmark Life Sciences rebranded as Alivus Life Sciences
Glenmark Life Sciences rebranded as Alivus Life Sciences

By IPP Bureau - January 19, 2025

The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space

GCPB revokes closure order of Aarti Pharmalabs’s Vapi plant
GCPB revokes closure order of Aarti Pharmalabs’s Vapi plant

By IPP Bureau - January 19, 2025

The company has paid an Interim Environmental Damage Compensation of Rs. 3.40 lakh to GPCB

Heraeus acquires Umicore’s Platinum API business outside of South America
Heraeus acquires Umicore’s Platinum API business outside of South America

By IPP Bureau - January 19, 2025

The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality

Caplin Steriles gets USFDA approval for Levetiracetam in Sodium Chloride Injection Infusion bags
Caplin Steriles gets USFDA approval for Levetiracetam in Sodium Chloride Injection Infusion bags

By IPP Bureau - January 18, 2025

This is the second Ready-To-Use Infusion bag (RTU Bags) ANDA drug product approved for Caplin Steriles

Indegene wins 2025 BIG Innovation Award for Hyper-automated AI solution
Indegene wins 2025 BIG Innovation Award for Hyper-automated AI solution

By IPP Bureau - January 18, 2025

Hyper-automated AI is a unified framework combining AI, ML, RPA, and NLQ to streamline data extraction, quality management, transformation, and actionable insights - all on a single platform

Datroway approved in the US for patients with previously treated metastatic HR-positive breast cancer
Datroway approved in the US for patients with previously treated metastatic HR-positive breast cancer

By IPP Bureau - January 18, 2025

Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030

Calquence combination approved in US for untreated mantle cell lymphoma
Calquence combination approved in US for untreated mantle cell lymphoma

By IPP Bureau - January 18, 2025

Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone

Latest Stories

Interviews

Packaging